How long can I take fostatinib? How long will the medication be used according to the treatment plan?

The length of use of fostamatinib depends on the patient's specific condition, response to treatment, and physician evaluation. This drug is mainly used to treat chronic immune thrombocytopenia (ITP) and is usually used as a second-line treatment option when first-line treatments (such as glucocorticoids or intravenous gamma globulin) are not effective. According to clinical trial data, some patients may see an increase in platelet count within 2 to 4 weeks of taking the drug, while for some patients, it may take about 12 weeks to see a stable effect. Therefore, it is generally recommended to continue the initial treatment phase for at least 3 months to evaluate the effectiveness of the drug.

If a patient fails to achieve a satisfactory platelet increase within the 12 weeks of treatment, the physician may consider adjusting the dose or changing the treatment regimen. However, for patients who respond to treatment, fostatinib can be used long-term to maintain platelet levels and reduce the risk of bleeding. Studies have shown that some patients can continue to take it for 6 months or even longer and maintain good platelet stability. During long-term use, doctors will regularly evaluate the efficacy and side effects of the drug to ensure its safety.

For some patients, doctors may recommend gradually reducing the dose or even discontinuing the medication if their condition is under stable long-term control. However, since ITP is a chronic immune disease, some patients may experience a drop in platelet count after stopping the drug. Therefore, it is necessary to conduct a blood test under the guidance of a doctor before stopping the drug, and adopt a method of gradually reducing the dose rather than stopping the drug suddenly to reduce the risk of recurrence.

In general, the duration of use of fostatinib varies from person to person and may be short-term or may require long-term maintenance treatment. Patients need to closely monitor platelet levels while taking the drug and have regular follow-up visits to ensure the effectiveness and safety of the drug. Whether to continue taking or stop taking the drug, you should strictly follow the doctor's advice and avoid adjusting the dose or interrupting the treatment on your own to avoid affecting the efficacy.

Reference materials:https://www.tavalisse.com/